Publications by authors named "Donovan G Kearns"
Topical medications have high utility in the treatment of psoriasis because of their localized effect and ability to be used as both monotherapy and adjunctive therapy. The American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) published guidelines in 2020 regarding the management of psoriasis with topical therapies. These guidelines are a framework that assist clinicians treating psoriasis patients with topical agents including steroids, calcineurin inhibitors (CNIs), vitamin D analogues, retinoids (tazarotene), emollients, keratolytics (salicylic acid), anthracenes (anthralin), and keratoplastics (coal tar).
View Article and Find Full Text PDFBackground: Interleukin (IL)-17 inhibitors are a newer class of biologic used to treat patients with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Objective: We compared evidence-based clinical practice guidelines (CPGs) from leading dermatological organizations for the use of IL-17 inhibitors in psoriasis.
Methods: Guidelines from the Joint American Academy of Dermatology-National Psoriasis Foundation (AAD-NFP) Guidelines, British Association of Dermatologists guidelines (BAD), and European S3 group (ES3) were all reviewed and compared.
In April 2019, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) released a set of guidelines regarding the management of psoriasis with a focus on its extracutaneous manifestations-comorbidities, mental health, psychosocial wellness, and quality of life (QOL). These guidelines provide the most up-to-date evidence on the screening and treatment recommendations for these disease comorbidities. The purpose of this review is to present the recommendations in a form that can be easily applied in clinical practice.
View Article and Find Full Text PDFThe aim of this review is to compare and contrast evidence-based clinical practice guidelines from global dermatological organizations for the use of ustekinumab in psoriasis. Clinical practice guidelines from the American Academy of Dermatology, National Psoriasis Foundation, British Association of Dermatologists, and European S3 were reviewed and compared. Practice guidelines from the three dermatological organizations are similar with regards to treatment dosage and initiation but differ in their recommendations for baseline screening and interval laboratory monitoring, treatment in patients undergoing surgery or receiving live vaccines, and treatment contraindications.
View Article and Find Full Text PDFIn 2020, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) released a set of guidelines for the management of psoriasis in adults with systemic nonbiologic therapies, including acitretin, apremilast, cyclosporine, fumaric acid esters, methotrexate, and tofacitinib. This review addresses dosing, efficacy, toxicity, drug-related interactions, and contraindications alongside evidence-based treatment recommendations for each systemic therapy. Important considerations for treatment such as drug selection, initiation of therapy, drug monitoring, and patient management also are discussed.
View Article and Find Full Text PDFArticle Synopsis
- Mild to moderate atopic dermatitis (AD) is common in both children and adults, typically managed with topical corticosteroids (TCS) and calcineurin inhibitors (TCIs), though their long-term use can cause adverse effects.
- A literature review was conducted to assess the safety and efficacy of new topical agents in clinical trials for AD, focusing on drugs like tapinarof, crisaborole, ARQ-151 cream, and ruxolitinib.
- The review found that these topical treatments showed significant improvements in disease severity and were well-tolerated, suggesting they are safe and effective alternatives for managing mild to moderate AD.
Article Synopsis
- The AAD and NPF updated guidelines in July 2019 focus on the use of phototherapy, primarily UV light, for managing psoriasis in adults.
- These guidelines summarize the latest evidence on dosing, indications, contraindications, and potential side effects of phototherapy, whether used alone or in tandem with other treatments.
- The review aims to present these recommendations in a practical format for easier application in clinical settings.
Clinical management of psoriasis patients during the COVID-19 pandemic.
J Dermatolog Treat
March 2022
Psoriasis is a systemic immune-mediated inflammatory disease that requires consistent treatment and follow-up. Given that COVID-19 will persist in the coming years, dermatologists need to adjust their practices accordingly to care for their patients, particularly psoriasis patients managed with systemic therapies. We provide guidelines for optimizing care for psoriasis patients, including considerations for medication management, lifestyle adjustments, and utilization of telemedicine.
View Article and Find Full Text PDFArticle Synopsis
- * The review analyzed 19 studies on biologic drugs, noting significant improvements in disease severity with drugs like lebrikizumab and tralokinumab, while other drugs like tezepelumab and etokimab showed no significant results for primary outcomes.
- * More extensive studies are needed to confirm the effectiveness of these therapies, especially in younger patients, as some biologics have potential as effective treatments for adults with moderate-to-severe AD.
Background: In late 2019 a viral pneumonia began to spread across the world. The viral disease, COVID-19, is now officially a pandemic, causing concern for the potential risk of systemic therapies for patients with psoriasis.
Objective: The purpose of this review is to analyze what is currently known about COVID-19 in regard to the safety of systemic treatment, and to provide guidelines for use in psoriasis during this pandemic.
Background: Generalized pustular psoriasis (GPP) is an uncommon variant of psoriasis that is characterized clinically by sterile pustule formation superimposed over inflamed, erythematous skin.
Methods: In June 2019, we conducted a systematic search of the PubMed Medline database using the keywords 'pustular psoriasis' and 'treatment'.
Results: First-line treatment for the condition consists of established therapies, such as acitretin, cyclosporine, methotrexate, and infliximab.